BRAF and Miyoshi myopathy: For MM patients harboring the cytoplasmic serine/threonine kinase B-Raf (BRAF) wild type, current guidelines recommend the use of monoclonal antibodies targeting immune checkpoint proteins such the anti-programmed death 1 (PD-1) (pembrolizumab or nivolumab) or the cytotoxic T-lymphocyte antigen 4 (CTLA-4) (ipilimumab) in combination with an anti-PD-1 therapy [6].